** Shares of Australian drugmaker Mayne Pharma MYX.AX fall as much as 7.7% to A$4.11, their lowest since Aug. 23
** Co provides no update on potential buyout interest, at its annual general meeting
** MYX earlier in the month said Jefferies to assist co in terms of looking for a possible bidder
** Stock posts its biggest intraday pct fall since Nov. 13
** Co says total revenue for the July-Oct period came in at A$132.5 mln ($86.32 mln), lower than the A$137 mln reported in the previous corresponding period
** Two analysts covering the stock rate it "buy" or higher, their median PT is A$2.0 – LSEG data
** Stock had fallen 32.7% this year, as of last close
($1 = 1.5349 Australian dollars)
(Reporting by Nichiket Sunil)
((Nichiket.Sunil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。